Table 2 Prognostic analysis of AKD associated with 1-year primary and secondary outcomes
sCr based AKD | eGFRsCr based AKD | eGFRsCysC based AKD | eGFRsCr+sCysC based AKD | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AKD n = 198 | non-AKD n = 4867 | P | AKD n = 337 | non-AKD n = 4728 | P | AKD n = 500 | non-AKD n = 4565 | P | AKD n = 314 | non-AKD n = 4751 | P | |
All-cause deatha, n(%) | 8 (4.0) | 63(1.3) | 12(3.6) | 59(1.3) | 9(1.8) | 62(1.4) | 9(2.9) | 62(1.3) | ||||
Crude HR (95% CI) | 3.15(1.51–6.58) | ref | 0.002 | 2.88(1.55–5.36) | ref | < 0.001 | 1.33(0.66–2.67) | ref | 0.43 | 2.21(1.10–4.44) | ref | 0.03 |
Adjusted HR (95% CI)d | 2.67(1.27–5.61) | ref | 0.01 | 2.19(1.17–4.10) | ref | 0.02 | 1.01(0.50–2.05) | ref | 0.97 | 1.86(0.92–3.76) | ref | 0.08 |
Stroke recurrenceb, n(%) | 9(4.6) | 175(3.6) | 17(5.0) | 167(3.5) | 19(3.8) | 165(3.6) | 11(3.5) | 173(3.6) | ||||
Crude HR (95% CI) | 1.28(0.65–2.49) | ref | 0.48 | 1.45(0.88–2.39) | ref | 0.14 | 1.05(0.66–1.69) | ref | 0.83 | 0.97(0.53–1.78) | ref | 0.91 |
Adjusted HR (95% CI)d | 1.22(0.62–2.39) | ref | 0.56 | 1.35(0.82–2.23) | ref | 0.25 | 0.94(0.58–1.52) | ref | 0.80 | 0.91(0.49–1.68) | ref | 0.76 |
Stroke disabilityc, n(%) | 32(16.2) | 459(9.4) | 56(16.6) | 435(9.2) | 69(13.8) | 422(9.2) | 42(13.4) | 449(9.5) | ||||
Crude OR (95% CI) | 1.85(1.25–2.74) | ref | 0.002 | 1.97(1.45–2.66) | ref | < 0.001 | 1.57(1.20–2.07) | ref | 0.001 | 1.48(1.05–2.08) | ref | 0.02 |
Adjusted OR (95% CI)d | 1.60(1.04–2.44) | ref | 0.03 | 1.51(1.08–2.11) | ref | 0.02 | 1.20(0.89–1.62) | ref | 0.23 | 1.26(0.88–1.82) | ref | 0.21 |